Stockholders' Equity

12 Months Ended

Dec. 31, 2024

Equity, Attributable to Parent [Abstract]

Stockholders' Equity

16. Stockholders' Equity

Zoetis is authorized to issue 6 billion shares of common stock and 1 billion shares of preferred stock.

In December 2021, our Board of Directors authorized a $3.5 billion multi-year share repurchase program. This program was completed as of December 31, 2024. In August 2024, our Board of Directors authorized a new multi-year share repurchase program of up to $6 billion of our outstanding common stock. As of December 31, 2024, there was $5.6 billion remaining under this authorization. Purchases of Zoetis shares may be made at the discretion of management, depending on market conditions and business needs.

Accumulated other comprehensive loss

Changes, net of tax, in accumulated other comprehensive loss, excluding noncontrolling interest, follow:

			Currency Translation Adjustments				Benefit Plans		Accumulated Other
	Cash Flow		Net Investment		Other Currency		Actuarial		Comprehensive
(MILLIONS OF DOLLARS)	Hedges		Hedges		Translation Adj		(Losses)/Gains		Loss
Balance, December 31, 2021	$	4	$	5	$	(756)	$	(17)	$	(764)
Other comprehensive gain/(loss), net of tax	86		36		(188)		13		(53)
Balance, December 31, 2022	90		41		(944)		(4)		(817)
Other comprehensive (loss)/gain, net of tax	(5)		(23)		—		6		(22)
Balance, December 31, 2023	85		18		(944)		2		(839)
Other comprehensive gain/(loss), net of tax	4		44		(147)		(2)		(101)
Balance, December 31, 2024	$	89	$	62	$	(1,091)	$	—	$	(940)